EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells

Molecular Biology Reports

Volumn 39, Issue 5, 2012, Pages 5465-5471

  Chen, Shu Jun ^a   Luan, Jing ^a   Zhang, Hai Shi ^b   Ruan, Can Ping ^b   Xu, Xin Yun ^b   Li, Qing Quan ^b   Wang, Nian Hong ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Breast cancer; Cell cycle; CyclinD1; EGFR; Multidrug resistance

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYCLIN D1; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; THYMIDINE; TOXEL; UNCLASSIFIED DRUG; VINCRISTINE; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CCND1 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; EGFR PROTEIN, HUMAN; MESSENGER RNA; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; S PHASE CELL CYCLE CHECKPOINT; BREAST TUMOR; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; NEOPLASM PROTEINS; PHENOTYPE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; S PHASE; UP-REGULATION;

EID: 84863748822     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-1347-4     Document Type: Article

References (20)

1. Stavrovskaya AA (2000) Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry 65:95-106
2. Eytan GD (2005) Mechanism of multidrug resistance in relation to passive membrane permeation. Biomed Pharmacother 59:90- 9 7. doi:10.1016/j.biopha.2005. 01.003
3. Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F (2006) The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr Drug Targets 7:893-9 0 9. doi:10.2174/ 138945006777709520
4. Chekhun VF, Lukyanova NY, Yurchenko OV, Kulik GI (2005) The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin. Exp Oncol 27:191-195
5. Chekhun VF, Ganina KP, Kulik GI, Solianik GI, Kunskaia LN, Gushchenko NN (2000) Influence of tumor drug resistance phenotype on the dynamics of cisplatin-induced changes of rat peripheral lymphocyte chromatin structure in Guerin's carcinoma. Tsitol Genet 34:11-17
6. Motwani M, Delohery TM, Schwartz GK (1999) Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 5:1876-1883
7. Motwani M, Schwartz GK (1998) Inappropriate cell cycle progression enhances the induction of apoptosis by flavopiridol in Taxol treated gastric cancer cells. Proc Am Assoc Cancer Res 39:190
8. Zhou Y, Ling XL, Li SW, Li XQ, Yan B (2010) Establishment of a human hepatoma multidrug resistant cell line in vitro. World J Gastroenterol 16:2291-22 97. doi:10.3748/wjg.v16.i18.2291
9. Zhuang DX, Liu YC, Ying Mao et al (2011) TMZ-induced PrPc/ par-4 interaction promotes the survival of human glioma cells. Int J Cancer. doi:10.1002/ijc.25985
10. Mirski SE, Gerlach JH, Cole SP (1987) Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47:2594-2598
11. Li QQ, Wang WJ, Xu JD et al (2007) Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Sci 98:1767-17 74. doi:10.1111/j.1349- 7006.2007.00593.x
12. Li QQ, Chen ZQ, Xu JD et al (2010) Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells. Cancer Sci 101:80-86. doi:10.1111/j.1349-7006.2009. 01372.x
13. Srivastava SK, Singh S (2004) Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferation activity of benzyl isothiocyanate against human pancreatic cancer cells. Carcinogenesis 25:1701-17 09. doi: 10.1093/carcin/bgh179
14. Meyers MB, Merluzzi VJ, Spengler BA, Biedler JL (1986) Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells. Proc Natl Acad Sci 83:5521-55 25. doi:10.1073/pnas.83.15.5521
15. Meyers MB, Shen WP, Spengler BA et al (1988) Epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem 38:87-97. doi:10.1002/jcb.240380203
16. Sherr CJ (1994) G1 phase progression: cycling on cue. Cell 79:551-5 55. doi:10.1016/0092-8674(94)90540-1
17. Kaufmann WK, Paules RS (1996) DNA damage and cell cycle checkpoints. FASEB J 10:238-247
18. Herbst RS (2004) Review of epidermal growth factor receptor biology. Int JRadiatOncolBiol Phys 59:21-26. doi:10.1016/j.ijrobp. 2003.11.041
19. Garcia R, Franklin RA, McCubrey JA (2006) EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 5:2820-28 26. doi:10.4161/cc.5.23.3535
20. Kitazaki T, Oka M, Nakamura Y et al (2005) Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49:337-3 43. doi:10.1016/j.lungcan.2005.03. 035